Amgen Inc. opted for a license arrangement rather than an equal partnership with Nuvelo Inc. for the Phase III-ready clot-dissolver alfimeprase, the lead product candidate that is the subject of a deal started almost three years ago. (BioWorld Today)

LONDON - ProStrakan Group Ltd. raised £22 million (US$40.3 million) from existing shareholders, giving it the leeway to launch an initial public offering at the time of its choosing in 2005 and enabling former Strakan institutional investors to recalibrate their shareholdings following the merger earlier this year with ProSkelia SA. (BioWorld International)